Abstract:
본 발명은 베트남 전통차로서 사용되고 있는 Ilex kudingcha (bitter tea)로부터 항산화 활성을 갖는 페놀릭계 성분을 함유하는 조성물에 관한 것이다. 더욱 상세하게는 베트남에서 전통차로 사용하여 왔지만 항산화 활성을 나타내는 물질에 대한 보고가 없었던 쿠딩차의 알코올 조추출물을 용매 분획한 후, 항산화 활성을 보이는 에틸아세테이트 분획으로부터 분리한 항산화 활성을 갖는 화합물 1 내지 화합물 9를 포함하는 쿠딩차 추출물을 유효성분으로 포함하는 항산화용 기능성 식품에 관한 것이다. 쿠딩차 추출물은 산화적 스트레스를 저해하는 기능이 우수하므로 쿠딩차 추출물을 포함하는 본 발명의 기능성 식품은 활성산소에 의해 유발되는 질환을 예방 또는 치료하기 위한 기능성 식품의 제조에 유용하게 사용될 수 있다. 식물소재, 항산화, 일렉스 쿠딩차, 추출물
Abstract:
The present invention relates to a composition for preventing or treating liver diseases containing an extract of fermented curcuma longa using fermented soybeans, or a curcuminoid derivative isolated therefrom. The composition suppresses the expression of α-SMA and TGF-β1 in liver tissues or liver cells, has an excellent effect on reducing the amount of TNF-α, and is capable of being used as a treatment for hepatitis, hepatic fibrosis, and liver cirrhosis, and health functional food. [Reference numerals] (1) Curcumalogin A; (2) Curcumalogin B; (3) Curcumalogin C; (4) Curcumalogin D; (5) 1-(4-hydroxy-3-methoxyphenyl)-7-(3,4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; (6) 5-hydroxy-1,7-bis(4-hydroxyphenyl)-4,6-heptadiene-3-one; (7) 1,7-bis(3,4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; (8) 1-(4-hydroxyphenyl)-7-(3,4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; (A) Curcumine; (AA) Control group; (B) Demethoxy curcumin; (BB) Compound process concentration(10μg/ml); (C) Bis-demethoxy curcumin
Abstract:
본 발명은 관중( Dryopteris crassirhizoma ) 추출물 및 이로부터 분리된 플로로글루시놀 유도체 화합물을 함유하는 코로나 바이러스 관련 질환의 예방 또는 치료용 조성물에 관한 것이다. 상기 조성물은 코로나 바이러스를 저해하는 효과가 뛰어나 바이러스성 감기 또는 장염의 치료제로 사용될 수 있으며, 화장품, 건강식품, 소독제, 동물사료, 동물약품 산업 등에도 응용될 수 있다.
Abstract:
The present invention relates to a composition for preventing or treating corona virus related diseases, which contains a Dryopteris crassirhizoma extract or phloroglucinol derivatives isolated from the same. The composition has an excellent inhibitory effect on corona virus to be used as a treatment for viral cold or enteritis, cosmetics, health foods, disinfectants, animal feed, and animal medicines. [Reference numerals] (AA,BB) Compound 4 (μg/ml)
Abstract:
The present invention relates to a composition containing a Polygala karensium extract and xanthone-based compounds isolated from the same for preventing or treating flu, avian influenza, swine influenza, or novel swine-origin influenza. The Polygala karensium extract and xanthone-based compounds isolated from the same effectively and non-selectively suppress neuraminidase of flu virus, avian influenza virus, swine influenza virus, novel swine-origin influenza, and Tamiflu resistant novel swine-origin influenza virus, thereby being used as a therapeutic agent for treating flu, avian influenza, swine influenza, and swine-origin influenza and being applied in cosmetic products, health foods, animal feeds, and an animal medicinal industry. [Reference numerals] (AA) Swine influenza virus (H1N1);(BB,HH,NN,TT) Compound 1;(CC,II,OO,UU) Compound 2;(DD,JJ,PP,VV) Compound 3;(EE,KK,QQ,WW) Compound 4;(FF,LL,RR,XX) Compound 5;(GG) Avian influenza virus (H9N2);(MM) Novel swine-origin influenza virus (novel H1N1);(SS) Novel swine-origin influenza virus resistant to Tamiflu (H1N1[H274Y])
Abstract:
PURPOSE: A compound which activates Erythrina abyssinica-derived AMPK is provided to prevent and treat diabetes, obesity, or metabolic syndrome with less cytotoxicity. CONSTITUTION: An Erythrina abyssinica extract for preventing or treating obesity or metabolic syndrome contains erythribyssin F, erythribyssin N, erythribyssin O, sigmoidin K, isosojagol, eryvarin, or erypoegin F. A health food or pharmaceutical composition for preventing or treating obesity or metabolic syndrome contains the Erythrina abyssinica extract as an active ingredient. The pharmaceutical composition also contains pharmaceutically acceptable carrier or excipient.